Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple

Michael Gundesen; Fredrik Schjesvold; Annette Juul Vangsted; Carsten Helleberg; Einar Haukås; Trine Silkjær; Elena Manuela Teodorescu; Bo Amdi Jensen; Tobias Slordahl; Jon Thor Asmussen; Hareth Nahi; Niels Abildgaard; Thomas Lund

doi:10.1016/S2152-2650(23)01577-X

Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple

Michael Gundesen, Fredrik Schjesvold, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Slordahl, Jon Thor Asmussen, Hareth Nahi, Niels Abildgaard, Thomas Lund

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Artikelnummer	OA-10
Tidsskrift	Clinical Lymphoma, Myeloma & Leukemia
Vol/bind	23
Udgave nummer	Suppl. 2
Sider (fra-til)	S6-S7
ISSN	2152-2650
DOI	https://doi.org/10.1016/S2152-2650(23)01577-X
Status	Udgivet - sep. 2023
Begivenhed	20th International Myeloma Society Annual Meeting and Exposition - Megaron Athens International Conference Centre, Athen, Grækenland Varighed: 27 sep. 2023 → 30 sep. 2023 https://www.myelomasociety.org/events/20th-ims-annual-meeting/

Konference

Konference	20th International Myeloma Society Annual Meeting and Exposition
Lokation	Megaron Athens International Conference Centre
Land/Område	Grækenland
By	Athen
Periode	27/09/2023 → 30/09/2023
Internetadresse	https://www.myelomasociety.org/events/20th-ims-annual-meeting/

Bibliografisk note

Abstrakt No. OA-10

Adgang til dokumentet

10.1016/S2152-2650(23)01577-X

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Gundesen, M., Schjesvold, F., Vangsted, A. J., Helleberg, C., Haukås, E., Silkjær, T., Teodorescu, E. M., Jensen, B. A., Slordahl, T., Asmussen, J. T., Nahi, H., Abildgaard, N., & Lund, T. (2023). Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple. Clinical Lymphoma, Myeloma & Leukemia, 23(Suppl. 2), S6-S7. Artikel OA-10. https://doi.org/10.1016/S2152-2650(23)01577-X

@article{09019f7929f74c648738ec7eeb6087de,

title = "Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple",

author = "Michael Gundesen and Fredrik Schjesvold and Vangsted, {Annette Juul} and Carsten Helleberg and Einar Hauk{\aa}s and Trine Silkj{\ae}r and Teodorescu, {Elena Manuela} and Jensen, {Bo Amdi} and Tobias Slordahl and Asmussen, {Jon Thor} and Hareth Nahi and Niels Abildgaard and Thomas Lund",

note = "Abstract No. OA-10; 20th International Myeloma Society Annual Meeting and Exposition, IMS 2023 ; Conference date: 27-09-2023 Through 30-09-2023",

year = "2023",

month = sep,

doi = "10.1016/S2152-2650(23)01577-X",

language = "English",

volume = "23",

pages = "S6--S7",

journal = "Clinical Lymphoma, Myeloma & Leukemia",

issn = "2152-2650",

publisher = "Elsevier",

number = "Suppl. 2",

url = "https://www.myelomasociety.org/events/20th-ims-annual-meeting/",

}

Gundesen, M, Schjesvold, F, Vangsted, AJ, Helleberg, C, Haukås, E, Silkjær, T, Teodorescu, EM, Jensen, BA, Slordahl, T, Asmussen, JT, Nahi, H, Abildgaard, N & Lund, T 2023, 'Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple', Clinical Lymphoma, Myeloma & Leukemia, bind 23, nr. Suppl. 2, OA-10, s. S6-S7. https://doi.org/10.1016/S2152-2650(23)01577-X

Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple. / Gundesen, Michael; Schjesvold, Fredrik; Vangsted, Annette Juul et al.
I: Clinical Lymphoma, Myeloma & Leukemia, Bind 23, Nr. Suppl. 2, OA-10, 09.2023, s. S6-S7.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple

AU - Gundesen, Michael

AU - Schjesvold, Fredrik

AU - Vangsted, Annette Juul

AU - Helleberg, Carsten

AU - Haukås, Einar

AU - Silkjær, Trine

AU - Teodorescu, Elena Manuela

AU - Jensen, Bo Amdi

AU - Slordahl, Tobias

AU - Asmussen, Jon Thor

AU - Nahi, Hareth

AU - Abildgaard, Niels

AU - Lund, Thomas

N1 - Abstract No. OA-10

PY - 2023/9

Y1 - 2023/9

U2 - 10.1016/S2152-2650(23)01577-X

DO - 10.1016/S2152-2650(23)01577-X

M3 - Conference abstract in journal

SN - 2152-2650

VL - 23

SP - S6-S7

JO - Clinical Lymphoma, Myeloma & Leukemia

JF - Clinical Lymphoma, Myeloma & Leukemia

IS - Suppl. 2

M1 - OA-10

T2 - 20th International Myeloma Society Annual Meeting and Exposition

Y2 - 27 September 2023 through 30 September 2023

ER -